Home > Insider Trading > Filing (0001209191-18-008219)

Filing Details

Accession Number:: 0001209191-18-008219
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-02-07 18:08:56
Reporting Period:: 2018-02-05

Accepted Time:: 2018-02-07 18:08:56
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
914475	Neurocrine Biosciences Inc	NBIX	Biological Products, (No Disgnostic Substances) (2836)	330525145

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1343124	Flint Christopher Obrien	12780 El Camino Real San Diego CA 92130	Former Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2018-02-05	1,500	$83.01	52,223	No	4	S	Direct
Common Stock	Disposition	2018-02-05	1,113	$83.40	54,310	No	4	S	Direct
Common Stock	Disposition	2018-02-06	1,014	$82.48	55,946	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	F	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option	Acquisiton	2018-02-05	9,250	$0.00	9,250	$81.49

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,250		2028-02-05	No	4	A	Direct

Footnotes

Sale of 1,500 shares of common stock issued upon vesting of 3,000 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,500) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth ina Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts theReporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 1,113 shares of common stock issued upon vesting of restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (2,087) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth ina Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts theReporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Payment of tax liability by withholding 1,014 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,636) maintained by the Reporting Person.
Represents option of which 1/24th of the shares underlying the option becomes vested and exercisable on March 5, 2018 and an additional 1/24th of the shares underlying the option becomes vested and exercisable each month thereafter.